Serum Says It Will Increase Monthly Production By 10 Crore In August, Bharat Biotech Promises 7.8 Crore | India News
NEW DELHI: Amid multiple states reporting a Covid-19 vaccine shortage, Serum institute and Bharat Biotech have presented to the Center their production plan for the next four months, informing that they can increase it to doses of 10 crore and 7.8 crore respectively by August, official sources said on Wednesday.
The sources said that the Union Ministry of Health and the Indian Comptroller General’s Office of Drugs had requested both companies their production plan for June, July, August and September.
Hyderabad-based Bharat Biotech’s Covaxin and Oxford-AstraZeneca’s Covishield, indigenously developed, manufactured by the Pune-based company. Serum Institute of India, are currently being used in India’s coronavirus inoculation campaign.
It was learned that Dr. V Krishna Mohan, permanent director of Bharat Biotech, informed the government that Covaxin production would rise to 3.32 crore in July and 7.82 crore in August, which will also remain in September.
Similarly, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, has reported that Covishield production will increase to 10 crore doses each in August and remain at that level in September, official sources said. . .
“We confirm that the amounts mentioned will be met in all circumstances. Additionally, we are doing our best using all of our resources to increase our Covishield production capacity. In view of this, production during June and July may also increase by some amount, “Singh said in a statement to the Health Ministry.
An inter-ministerial group, consisting of Rajneesh Tingal, Co-Secretary of the Department of Pharmaceutical Products, Dr. Mandeep Bhandari, Co-Secretary of the Ministry of Health, which was set up to facilitate increased domestic vaccine manufacturing capacity, had visited the production facilities of both the Serum Institute of India and Bharat Biotech in April.
Various states and UT, including Delhi, Maharashtra, Karnataka and Telangana have decided to opt for global tenders for the acquisition of vaccines against the coronavirus and the national supply is falling short to meet the growing demand.
Meanwhile, Delhi’s Chief Deputy Minister Manish Sisodia said on Wednesday that Bharat Biotech informed the Delhi government that it cannot provide “additional” doses of Covaxin to the national capital.
The Covaxin stock in Delhi has ended and as a result, around 100 vaccination centers established in 17 schools have been closed, he said.
The Ministry of Science and Technology had said in a statement on April 16 that the production capacity of Covaxin developed locally will double by May-June 2021 and then increase almost 6-7 times by July-August 2021.